Organ Transplantation: Development in The Surgical Procedures Has Promoted The Growth of Market at a CAGR of 9.50% During Forecasted Period 2023-2032

Pune, India, November 2022 /MRFR Press Release/- Market Research Future published a half-cooked research report on global organ transplantation market. 

Market Highlights

Organ transplantation is the replacement of the diseased or damaged organ with a health organ. Organs such as a kidney may be donated by living donors or harvested from brain-dead organ donors. Organ dysfunction caused due to severe injuries, cancer, organ failure and/or genetic disorders necessitate the requirement for organ transplant procedures. Advances in technology and development in the medical sector has made transplantation possible. Kidney, heart, lungs, liver and many more can be transplanted. An increasing number of organ transplantation surgeries across the globe are the major driving factor for the growth of the market. Technological development, increasing prevalence of chronic diseases, rising aging population and changing lifestyle has also contributed to the growth of the market. However, high cost of treatment and increasing incident of organ failure has hampered the growth of the market. Global organ transplantation market is expected to USD 15.16 billion by 2032, at CAGR of 9.50% during the forecast period (2023 - 2032).

Segmentation:

Global organ transplantation market is segmented on the basis of type of organ, into heart, kidney, liver, lungs, and other. On the basis of products, they are segmented into organ preservation solutions, transplant diagnostics, tissue products and other. On the basis of type of transplant the market is segmented into autograft, allograft and allotransplantation, xenograft and xenotransplantation and other.

On the basis of treatment the market is segmented into analgesic, immunosuppressant and other. Immunosuppressant is further segmented into calcineurin inhibitors, mTOR inhibitor, antiproliferative agents, steroids and other. Calcineurin Inhibitors are sub segmented into tacrolimus and cyclosporine. mTOR inhibitor is sub segmented into sirolimus and everolimus.

On the basis of end users the market is sub segmented into hospitals, transplant centers and other. 

Figure 1- Global organ transplantation market, by type of organ

     Source- Annual reports, Press release, White paper, Company Presentation

Regional Analysis

On a regional basis, the global organ transplantation market is segmented into America, Europe, Asia Pacific and Middle East & Africa. America accounts for the largest market, owing to the huge number of people suffering from chronic diseases. An increasing number of organ transplantation, rising aging population and developments in the technology has also contributed for the growth of the market. Europe has the second largest market which is followed by Asia Pacific. Encouraging the start of new organizations and research, developed infrastructure and increasing healthcare expenditure has driven the Europe market. Asia Pacific has the growing market of organ transplantation. Rapid development in the healthcare sector, availability of skilled professionals and large diseases population pool is expected to fuel the growth of the market. Whereas, due to presence of poor economies in Africa and limited growth in healthcare sector is responsible for the lowest market of Middle East & Africa 

Competitive Analysis

 Sources- Annual reports, Press Release, White paper, Company Presentation

The major key player for the global organ transplantation market are Novartis International AG (Switzerland), Terumo Medical Corporation (US), Transonic (US), F. Hoffmann-La Roche Ltd. (Switzerland), Astellas Pharma, Inc (Japan), Preservation Solutions, Inc. (US),  OrganOX Limited (UK), Bio Med Pvt. Ltd. (US), Transplant Biomedical (UK), TransMedic, Inc. (US), Accord Healthcare GmbH (Spain), Sanofi (France), Pfizer, Inc. (US), Veloxis Pharmaceuticals A/S (Denmark), GlaxoSmithKline Plc. (UK) 

Global organ transplantation market is a competitive market. Major companies are investing in R&D so as to introduce more innovative and efficient methods and devices as they are under constant pressure to launch new and cost-effective method.

Novartis International AG is a Swiss multinational company headquartered in Switzerland and is one of the largest pharmaceutical companies. They are the leading manufacturer of analgesic drugs. In 2016, company has acquired Selexys Pharmaceuticals to increase its market. Company has launched, Zortress is the first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of  Organ Transplantation Market Research Report